Identification of Widely Applicable Tumor-Associated Antigens for Breast Cancer Immunotherapy
Final rept. 15 Sep 2001-31 Dec 2005
JOHNS HOPKINS UNIV BALTIMORE MD
Pagination or Media Count:
This study aims to identify widely applicable TAAs for immunotherapy against breast cancer. The rationale is to screen for candidate genes that are commonly over--expressed in human breast cancers, but not in benign breast tissue. These genes may reasonably serve as targets for antigen-specific in1munotherapy against breast cancer. The study began with pp32 gene family members, which had been shown differentially and alternatively expressed in most human breast cancers. In general, benign breast tissues express pp32, a tumor suppressor, whereas breast cancers express tumorigenic family members, including pp32rl and pp32r2. The purpose of this study is to identify tumor-associated antigens TAA in pp32rl and pp32r2, then test their suitability as immunotherapeutic targets in breast cancer. In addition to pp32 gene family, BCOX1, BCOX2, and EBP50 were also identified as potential target for breast cancer immunotherapy.
- Medicine and Medical Research